Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by 1900 Wealth Management LLC

1900 Wealth Management LLC increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,294 shares of the medical research company’s stock after acquiring an additional 40 shares during the period. 1900 Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $687,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently modified their holdings of the business. Raleigh Capital Management Inc. increased its position in Thermo Fisher Scientific by 49.1% in the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock worth $41,000 after purchasing an additional 27 shares during the last quarter. Cedar Mountain Advisors LLC lifted its position in shares of Thermo Fisher Scientific by 107.0% in the 4th quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock worth $47,000 after acquiring an additional 46 shares during the period. Operose Advisors LLC lifted its position in shares of Thermo Fisher Scientific by 250.0% in the 3rd quarter. Operose Advisors LLC now owns 105 shares of the medical research company’s stock worth $53,000 after acquiring an additional 75 shares during the period. Financial Connections Group Inc. bought a new position in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $53,000. Finally, Valley National Advisers Inc. lifted its position in shares of Thermo Fisher Scientific by 40.5% during the 3rd quarter. Valley National Advisers Inc. now owns 111 shares of the medical research company’s stock worth $56,000 after buying an additional 32 shares during the period. Institutional investors own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

TMO has been the subject of several research reports. The Goldman Sachs Group lifted their target price on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. HSBC lifted their target price on Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock a “buy” rating in a report on Wednesday, April 17th. Citigroup started coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They issued a “neutral” rating and a $620.00 price target on the stock. Barclays lowered Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and upped their target price for the stock from $475.00 to $555.00 in a report on Wednesday, January 24th. Finally, Raymond James boosted their price target on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. Five research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $604.69.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the transaction, the chief executive officer now owns 49,155 shares of the company’s stock, valued at approximately $27,311,992.65. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the transaction, the chief executive officer now owns 49,155 shares of the company’s stock, valued at approximately $27,311,992.65. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 5,547 shares of Thermo Fisher Scientific stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $550.62, for a total transaction of $3,054,289.14. Following the transaction, the chief executive officer now directly owns 43,608 shares in the company, valued at approximately $24,011,436.96. The disclosure for this sale can be found here. In the last quarter, insiders have sold 50,277 shares of company stock valued at $28,513,384. 0.32% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Up 4.1 %

Shares of TMO traded up $22.42 during trading hours on Tuesday, hitting $570.80. The stock had a trading volume of 905,502 shares, compared to its average volume of 1,540,551. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39. The firm has a 50 day simple moving average of $571.30 and a 200-day simple moving average of $528.18. The firm has a market capitalization of $217.88 billion, a P/E ratio of 35.49, a price-to-earnings-growth ratio of 2.30 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, beating the consensus estimate of $5.64 by $0.03. The company had revenue of $10.89 billion during the quarter, compared to the consensus estimate of $10.73 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The firm’s revenue for the quarter was down 4.9% compared to the same quarter last year. During the same period last year, the business posted $5.40 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.51 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were given a $0.39 dividend. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date was Thursday, March 14th. This represents a $1.56 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.10%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.